Related Experiment Video
Updated: Dec 25, 2025
07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
978
LncRNA-ATB in cancers: what do we know so far?
Feng Tang1,2, Yadi Xu3,4, Hongliang Wang3,4
1Department of Neurosurgery, the Second Affiliated Hospital of Anhui Medical University, Cerebral Vascular Disease Research Center, Anhui Medical University, 678 Fu Rong Road, Hefei, 230601, Anhui Province, China. tf172126@163.com.
Molecular Biology Reports
|April 6, 2020
Summary
Long noncoding RNAs (lncRNAs) show promise as cancer biomarkers. This review focuses on lncRNA-ATB, exploring its role in tumor development and potential as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cancer remains a leading cause of death globally, with limited success from aggressive treatments.
- Long noncoding RNAs (lncRNAs) are increasingly recognized for their potential as cancer biomarkers and therapeutic targets.
- LncRNA-ATB, a TGF-β-activated long noncoding RNA, is implicated in tumor development and progression.
Purpose of the Study:
- To review the functions and mechanisms of lncRNA-ATB in various cancers.
- To evaluate the potential of lncRNA-ATB as a cancer biomarker.
- To discuss lncRNA-ATB as a possible therapeutic target for cancer treatment.
Main Methods:
- Literature review of studies on lncRNA-ATB expression and function in cancer.
- Analysis of data linking lncRNA-ATB to tumor development, progression, and clinical characteristics.
- Synthesis of current evidence on lncRNA-ATB's role in oncogenesis.
Main Results:
- Aberrant expression of lncRNA-ATB is observed in several types of cancer.
- lncRNA-ATB plays a significant role in tumor development and progression.
- Abnormal lncRNA-ATB levels correlate with specific clinical features of tumors.
Conclusions:
- lncRNA-ATB is a key player in cancer progression.
- lncRNA-ATB holds promise as a diagnostic biomarker for cancer.
- Targeting lncRNA-ATB may offer a novel therapeutic strategy for cancer treatment.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
9.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
02:39lncRNA - Long Non-coding RNAs
3.3K
3.3K
03:18Non-LTR Retrotransposons
13.0K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.0K
02:55The Nucleolus
10.1K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
10.1K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:20The Retinoblastoma Gene
4.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K